B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

E Wiesik-Szewczyk, M OlesinskaInstitute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, PolandAbstract: Systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown etiology, and the limited available therapeutic options for this disease, are frustrating to both c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wiesik-Szewczyk E, Olesinska M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/432219feb2614506aef7b96cba088830
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:432219feb2614506aef7b96cba088830
record_format	dspace
spelling	oai:doaj.org-article:432219feb2614506aef7b96cba0888302021-12-02T00:16:59ZB-cell targeted therapy in systemic lupus erythematosus: potential of rituximab1177-54751177-5491https://doaj.org/article/432219feb2614506aef7b96cba0888302012-09-01T00:00:00Zhttp://www.dovepress.com/b-cell-targeted-therapy-in-systemic-lupus-erythematosus-potential-of-r-a11112https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491E Wiesik-Szewczyk, M OlesinskaInstitute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, PolandAbstract: Systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown etiology, and the limited available therapeutic options for this disease, are frustrating to both clinicians and patients. However, recent advances in the understanding of disease mechanisms have given rise to numerous studies on specific approaches to SLE treatment. Rituximab, the first chimeric, mouse-human monoclonal antibody which is directed against CD20, seems to be a new therapeutic option. The purpose of this review is to explain the current clinical evidence on the therapeutic use of rituximab in adult SLE patients. Two randomized clinical trials with rituximab (the EXPLORER and LUNAR studies) failed to prove efficacy of this drug on SLE. Ongoing data analysis continues to explain the reasons behind why this treatment fails to work. However data from open source and observational studies contrast with clinical trials results. The global analysis of this data supports the off-label use of rituximab in subsets of SLE that are refractory to standard treatment.Keywords: B cells, systemic lupus erythematosus, rituximab, off-label use, clinical trialsWiesik-Szewczyk EOlesinska MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 347-354 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Wiesik-Szewczyk E Olesinska M B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
description	E Wiesik-Szewczyk, M OlesinskaInstitute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, PolandAbstract: Systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown etiology, and the limited available therapeutic options for this disease, are frustrating to both clinicians and patients. However, recent advances in the understanding of disease mechanisms have given rise to numerous studies on specific approaches to SLE treatment. Rituximab, the first chimeric, mouse-human monoclonal antibody which is directed against CD20, seems to be a new therapeutic option. The purpose of this review is to explain the current clinical evidence on the therapeutic use of rituximab in adult SLE patients. Two randomized clinical trials with rituximab (the EXPLORER and LUNAR studies) failed to prove efficacy of this drug on SLE. Ongoing data analysis continues to explain the reasons behind why this treatment fails to work. However data from open source and observational studies contrast with clinical trials results. The global analysis of this data supports the off-label use of rituximab in subsets of SLE that are refractory to standard treatment.Keywords: B cells, systemic lupus erythematosus, rituximab, off-label use, clinical trials
format	article
author	Wiesik-Szewczyk E Olesinska M
author_facet	Wiesik-Szewczyk E Olesinska M
author_sort	Wiesik-Szewczyk E
title	B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_short	B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_full	B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_fullStr	B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_full_unstemmed	B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_sort	b-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/432219feb2614506aef7b96cba088830
work_keys_str_mv	AT wiesikszewczyke bcelltargetedtherapyinsystemiclupuserythematosuspotentialofrituximab AT olesinskam bcelltargetedtherapyinsystemiclupuserythematosuspotentialofrituximab
_version_	1718403796389855232

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

Ejemplares similares